thymia began with neuroscientist Dr. Emilia Molimpakis’ desire to turn years of research into something practical, usable and meaningful to everyday people. After 12 years studying neuroscience and language, seeing a close friend with depression not receive the help she needed quickly enough gave her a personal reason to leave academia. Founded in 2020 with Dr. Stefano Goria, the company combines their complementary expertise with a practical goal: making voice a useful signal for health, wellbeing and safety.

That goal has developed into voice biomarker technology that analyses just 15 seconds of speech for signals related to mental and physical health, including depression, anxiety, fatigue and stress. The company also reports a breakthrough in detecting active type 2 diabetes from 20 seconds of speech. Rather than building a standalone consumer product, the technology is designed as an intelligence layer that can plug into different platforms wherever voice is used.

Building that capability has required significant investment in the science and data behind the product. The team spent 6.5 years gathering its own dataset, with consent and detailed clinical annotations, to build and validate its models. thymia says it now has the world’s largest dataset of its kind and became the first voice biomarker company globally to achieve registered medical-device status.

Although healthcare was initially expected to be the company’s primary market, it proved slower to adopt the technology. The team instead found stronger demand in safety-critical settings and voice AI, where detecting signals such as fatigue and stress can create more immediate value. Automotive has become one such application, with the technology able to detect signs of driver fatigue in real time.

Moving into cars also presented a practical challenge. Standard noise-filtering tools can remove the acoustic signals the technology relies on, particularly in noisy environments. The team therefore built its own noise-filtering and cancellation systems, enabling real-time voice analysis in applications such as driver fatigue detection. The company sees this beginning with safety, then improving the overall in-cabin experience through the insights thymia’s technology generates into how the driver is doing.

Looking ahead, thymia aims to scale primarily through partnerships, bringing its technology into more platforms rather than developing a standalone consumer product. For Dr. Emilia Molimpakis, the greater motivation is not a particular route to exit, but enabling technology to reach more people and create safety, health and experience value. The company’s next phase includes scaling internationally, with the US a priority.